Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), which enhance insulin secretion and suppress glucagon release in a glucose-dependent manner. It is eliminated primarily via the biliary/gastrointestinal route.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
Standard dose: 5 mg orally once daily, taken with or without food.
## Pediatric Dosing
Safety and effectiveness in pediatric patients (under 18 years) have not been established. Use is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Combination Therapy:** When used with insulin or an insulin secretagogue (e.g., sulfonylurea), consider lowering the dose of the insulin or secretagogue to reduce the risk of hypoglycemia.
## Contraindications
* Hypersensitivity to linagliptin or any component of the formulation.
* History of angioedema or anaphylaxis related to DPP-4 inhibitors.
## Adverse Effects
* **Common:** Nasopharyngitis, hyperuricemia.
* **Serious:** Acute pancreatitis (discontinue immediately if suspected), bullous pemphigoid, severe arthralgia, and hypersensitivity reactions (anaphylaxis, angioedema, exfoliative skin conditions).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin plasma concentrations. If co-administration is necessary, monitor glycemic control closely.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months) and fingerstick blood glucose monitoring.
* **Pancreatitis:** Monitor for signs of severe, persistent abdominal pain.
* **Skin:** Monitor for blistering or erosions suggestive of bullous pemphigoid.
## Clinical Pearls
* Linagliptin is unique among DPP-4 inhibitors as it does not require renal dose adjustment, making it a preferred choice for patients with chronic kidney disease.
* It is weight-neutral and has a low risk of hypoglycemia when used as monotherapy.
* If a dose is missed, it should be taken as soon as possible, but do not take two doses at the same time.
***
**Disclaimer:** This information is for educational purposes and does not substitute for professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors with the official product labeling and clinical guidelines before prescribing or administering medication.
